Summary:
Systemic Lupus Erythematosus: A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active
Qualified Participants May Receive:
Free patient visits
May include compensation for time and travel